DBV Technologies S.A. (NASDAQ:DBVT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $48.50.

A number of brokerages have recently issued reports on DBVT. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. Citizens Jmp raised their price objective on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research note on Tuesday, June 30th. Wall Street Zen lowered DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday. HC Wainwright restated a “buy” rating on shares of DBV Technologies in a report on Tuesday, June 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DBV Technologies in a research report on Monday, June 29th.

DBV Technologies Price Performance

DBV Technologies stock traded up $0.70 during midday trading on Tuesday, hitting $16.32. 104,139 shares of the stock were exchanged, compared to its average volume of 296,459. DBV Technologies has a 1 year low of $8.51 and a 1 year high of $26.18. The firm has a market cap of $966.01 million, a P/E ratio of -3.66 and a beta of -0.95. The company has a 50 day moving average price of $17.89 and a two-hundred day moving average price of $19.75.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $1.11 million. DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. As a group, analysts predict that DBV Technologies will post -0.38 EPS for the current year.

Institutional Trading of DBV Technologies

Institutional investors have recently added to or reduced their stakes in the stock. Artisan Partners Limited Partnership boosted its stake in DBV Technologies by 6,273.4% during the 4th quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock valued at $63,435,000 after acquiring an additional 3,257,135 shares during the last quarter. Vivo Capital LLC increased its position in shares of DBV Technologies by 8.4% in the 1st quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock worth $55,726,000 after purchasing an additional 205,943 shares during the last quarter. Siren L.L.C. acquired a new stake in shares of DBV Technologies in the 4th quarter valued at about $35,606,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of DBV Technologies in the 2nd quarter valued at about $9,659,000. Finally, MPM Bioimpact LLC bought a new position in shares of DBV Technologies during the second quarter worth about $9,649,000. 71.74% of the stock is owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.